NCT06845254View on ClinicalTrials.gov

Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

October 1, 2025

Study Completion Date

December 1, 2026

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)

Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + Xuesaitong soft capsule, 0.33g/ tablets, 2 tablets each time, twice a day. The treatment period is 12 weeks.

DRUG

placebo capsule

Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + placebo capsule, 0.33g/ tablets, 2 tablets each time, twice a day. The treatment period is 12weeks.

Trial Locations (1)

Unknown

Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing

All Listed Sponsors
lead

Xiyuan Hospital of China Academy of Chinese Medical Sciences

OTHER